Related Experiment Videos
Disease modifiers: making the right therapeutic choices for our patients
1Department of Internal Medicine, University of Alabama, Birmingham, Alabama 35294, USA. larry.moreland@ccc.uab.edu
Abstract:
Patients with rheumatoid arthritis (RA) who suffer an inadequate response to disease modifying antirheumatic drugs and biologic therapies represent a large segment of the RA population, so treating these patients is a major issue for physicians. The 4 case studies discussed in this article were presented at an American College of Rheumatology 2006 Annual Meeting Satellite Symposium and highlight some of the key issues for patients who are not responding adequately to current therapies. These issues include which therapy to consider next for maintaining tight control and maximizing outcomes in patients, and what is the rightful place of newly approved therapies within the current RA treatment armamentarium. Included here are the Audience Response System (ARS) results from the symposium, which will allow readers to compare their answers with that of the audience; this may help physicians in the decision-making process for their patients.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenomics: Identification of New Drug Targets
Drug Therapy
Antianxiety Medications
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...